TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02638467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Subjects will receive 400mg of bosutinib once daily from day +30 after transplant, by mouth with food, preferably in the morning. Bosutinib will also be administered from day at least -45 to day -15 to assess the sensitivity of patient CML to this TKI.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Transplant
Description: Samples of the unrelated stem cell graft shall be characterised with respect to the number of CD34 positive cells per kg body weight of the recipient.~The number of transplanted CD34 positive cells per kg body weight (BW) of the recipient shall be recorded in the Case Report Form (CRF). If the transplant was cryopreserved the number of viable CD34 positive cells has to be determined after thawing and documented.~The goal is to transplant \> 3 x 106 CD34+ cells/kg BW recipient from bone marrow or \> 3 x 108 nucleated cells/kg BW recipient from bone marrow

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone Marrow cells
Study: NCT02283892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Checklist
Description: 3 page checklist with suggestions of possible diagnosis according to clinical presentation of patients presenting with dyspnea or cough; also suggests diagnostic tests that are likely to be useful in each situation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional evaluation
Description: Physician evaluation without the use of checklists
Study: NCT02318368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ficlatuzumab
Study: NCT03699657

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DSM
Description: Monopolar RFA using dual switching mode (DSM)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SSM
Description: Monopolar RFA using single switching mode (SSM)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Separable clustered electrodes
Description: A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Separable clustered electrodes
Description: A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
Study: NCT04165200

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood and feces samples
Description: Blood samples are going to be taken by puncturing peripheral vein extraction with 10 ml of venous blood for later biweekly to monitor in person and therefore monitor immune status with biomarkers T lymphocyte subclass CD4 and viral load. A total of four blood samples will be taken at weeks 4, 8, 12 and 24 of recruitment.~A total of four feces samples are going to be required during the study, to evaluate the changes on the microbiota of the patient. 1 week before the patients start their HAART, the same day the patients initiate their HAART, 8 weeks after they started HAART and 24 weeks after HAART.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Blood and feces samples
Description: Blood samples are going to be taken by puncturing peripheral vein extraction with 10 ml of venous blood for later biweekly to monitor in person and therefore monitor immune status with biomarkers T lymphocyte subclass CD4 and viral load. A total of four blood samples will be taken at weeks 4, 8, 12 and 24 of recruitment.~A total of four feces samples are going to be required during the study, to evaluate the changes on the microbiota of the patient. 1 week before the patients start their HAART, the same day the patients initiate their HAART, 8 weeks after they started HAART and 24 weeks after HAART.
Study: NCT03783364

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Pre- or postoperative acellerated irradition in 5 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Pre- or postoperative acellerated irradition in 5 fractions
Study: NCT02318368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study: NCT03673527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical formulation of tacrolimus
Description: Topical application of tacrolimus twice daily for 14 days (one dose on Day 14).
Study: NCT03045991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise training
Description: The aerobic exercise program using progressive resistive stationary bicycle training which will contain warm-up, resistive physical exercise, and cool-down. The training resistance will increase with improvement of participants' performance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control training
Description: The control training program will receive 30 minutes non-aerobic exercise training, including stretching muscle skills, joint mobility exercises; in addition to one 30-minute session of unstructured mental activities, such as reading books or reading educational films.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive training
Description: The computerized cognitive training program will be implemented with the brainHQ to target abilities of visuospatial processing, attention, memory, and executive function. The level of the training program will become more difficult with progress in participants' targeted cognitive abilities.
Study: NCT03365752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine
Description: A spinal anesthetic with 2% chloroprocaine (2cc or 40 mg) will be performed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine
Description: A spinal anesthetic with 1.5% Mepivacaine (3cc or 45 mg) will be performed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthetics
Description: General anesthetics will be administered intravenously
Study: NCT04034537

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cPSTA
Description: The cPSTA System is a medical device system that uses passive tomography to analyze a patient's phase space data to identify the presence of significant coronary artery disease. The cPSTA System consists of several components that work together to obtain, transmit, analyze the data, and display the results, including the Phase Signal Acquisition System (PSAQ System), which is the Phase Signal Recorder (PSR) and the Phase Signal Data Repository (PSDR); analytical software; and secure web portal. For this study only the PSAQ System is used by the clinical site for the purposes of acquiring and transmitting the signal. All enrolled patients will perform cPSTA signal recording.
Study: NCT03598335

Intervention type: DEVICE
Intervention: Ultrasound
Description: Ultrasound imaging of women arriving at clinic for routine care

Intervention type: DEVICE
Intervention: Ultrasound
Description: Ultrasound imaging of women arriving at clinic for routine care

Intervention type: DEVICE
Intervention: Ultrasound
Description: Ultrasound imaging of women arriving at clinic for routine care
Study: NCT01976702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Behavioral Skills Training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Behavioral Skills Training
Study: NCT00922402

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive insulin infusion
Description: The intensive control of glycemia is obtained with a shared in-hospital insulin infusion protocol, supported by the use of a continuous glucose monitoring system (Medtronic Guardian REAL Time). Any sudden variation of glycemia levels and/or alarms, as indicated by the device, has to be confirmed with a finger-stick before any therapy modification.~In-hospital management is subdivided in a 2-day intensive and a 3-day post-intensive phase.
Study: NCT00800696

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oral care
Description: The study group will have their teeth brushed three times a day by the nursing staff by using a suction connected toothbrush, daily examination of the oropharynx by the nursing staff, and use of chlorhexidine varnish or another suitable antibacterial agent in the oropharynx
Study: NCT02342288

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head raised 10 degrees
Description: Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. Head was raised to 10 degrees. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Head in neutral position
Description: Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
Study: NCT02024425

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Functional bioactive supplement
Description: 1,25g of antioxidant extracted from rosemary, 18g of oligosaccharides derived from lactulosa and 1,25g of bioactive peptides

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control supplement
Study: NCT03402594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow oxygen
Description: Heated humidified high flow oxygen cannula (Optiflow; temperature of 34°C and fractional inspired oxygen of 0.24) with a flow rate of 20 liter/minute
Study: NCT00942253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dopamine Agonist and Exercise
Description: Dialysis patients will receive dopamine agonist or placebo for 24 weeks following a 24 weeks period of combined treatment with dopamine agonist or placebo and aerobic intradialytic exercise.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dopamine Agonist and Exercise
Description: Dialysis patients will receive dopamine agonist or placebo for 24 weeks following a 24 weeks period of combined treatment with dopamine agonist or placebo and aerobic intradialytic exercise.
Study: NCT03393130

Intervention type: DIAGNOSTIC_TEST
Intervention: APOE genotyping
Description: APOE genotyping and broad cognitive assessment expressed as a median T-score of the following tests (with cognitive domains assessed in brackets) Trail Making Part A (processing speed), Trail Making Part B (executive function), One Back test (working memory), List Learning Task (Immediate recall, visual learning, delayed recall and recognition discrimination).

Intervention type: DIAGNOSTIC_TEST
Intervention: APOE genotyping
Description: APOE genotyping and broad cognitive assessment expressed as a median T-score of the following tests (with cognitive domains assessed in brackets) Trail Making Part A (processing speed), Trail Making Part B (executive function), One Back test (working memory), List Learning Task (Immediate recall, visual learning, delayed recall and recognition discrimination).
Study: NCT03607162

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DIAFEVER algorithm
Description: PCT rapid test-based predictive algorithm
Study: NCT01459471

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Staple line reinforcement during sleeve gastrectomy
Study: NCT03402594

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low flow oxygen
Description: Oxygen cannula with a flow rate of 2 liter/minute
Study: NCT02261064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/Amlodipine low dose
Study: NCT00003499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Low-grade non-Hodgkin's lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT01256008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: The subjects will receive standardized CBT treatment regularly for 9 sessions(once per week in the first month and once half a month in the second and third months), and each session will last for about 60 minutes.The treatment includes three steps:Concept stage (the first and second sessions): establishment of therapeutic relationships with the subjects; Skills acquisition and repeat stage (the third session to the 8th session): clarification of sources of stress, patients' cognitive and behavioral response to stress. Application and complete price segment (the 9th session): return visit to test efficacy of psychological intervention.
Study: NCT00288041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study: NCT01052636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interdisciplinary intervention program
Description: The intervention program developed for this study included three components: geriatric consultation service, rehabilitation program, and discharge-planning service.
Study: NCT03080051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-952
Description: Subjects will undergo PET imaging using \[18F\]MNI-952, a PET radioligand for imaging tau.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Florbetapir
Description: Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-952.
Study: NCT03377569

Intervention type: OTHER
Intervention: Sleep, PD and DBS
Description: Sleep, PD and DBS

Intervention type: OTHER
Intervention: Sleep, PD and DBS
Description: Sleep, PD and DBS
Study: NCT02261064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine low dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/Amlodipine high dose
Study: NCT03244384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystoscopy
Description: Undergo a cystoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cystoscopy
Description: Undergo a cystoscopy
Study: NCT01948713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening of pelvic floor muscles.
Description: Kegel exercises kinesiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening of pelvic floor muscles.
Description: Kegel exercises kinesiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening of hip muscles.
Description: Kegel exercises and strengthening of hip muscles as Gluteus Maximus and Medius and adductor muscles
Study: NCT04034563

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 1) Risk of metachronous advanced neoplasia at 3-year, beyond 3 years surveillance colonoscopy
Description: 3-year group: High-risk subjects who have baseline colonoscopy done in 2014, 2015 and 2016 and will be eligible for 3-year surveillance colonoscopy in 2017-2019.~Beyond 3 years group: High-risk subjects who had screening colonoscopy prior 3 years, but not received or scheduled for a surveillance colonoscopy- either due to non-adherence or limited access to surveillance colonoscopy will be eligible for surveillance colonoscopy in 2017-2019.~For the surveillance interval beyond 3 years group, recruitment will be prioritizing to subjects who had the screening colonoscopy at the earliest date. This will in part ensure that subjects in this group will consist those with the longest surveillance interval, leading to an applicable estimation of the risk of metachronous advanced neoplasia beyond 3 years surveillance interval.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 1) Risk of metachronous advanced neoplasia at 3-year, beyond 3 years surveillance colonoscopy
Description: 3-year group: High-risk subjects who have baseline colonoscopy done in 2014, 2015 and 2016 and will be eligible for 3-year surveillance colonoscopy in 2017-2019.~Beyond 3 years group: High-risk subjects who had screening colonoscopy prior 3 years, but not received or scheduled for a surveillance colonoscopy- either due to non-adherence or limited access to surveillance colonoscopy will be eligible for surveillance colonoscopy in 2017-2019.~For the surveillance interval beyond 3 years group, recruitment will be prioritizing to subjects who had the screening colonoscopy at the earliest date. This will in part ensure that subjects in this group will consist those with the longest surveillance interval, leading to an applicable estimation of the risk of metachronous advanced neoplasia beyond 3 years surveillance interval.
Study: NCT03377569

Intervention type: OTHER
Intervention: Sleep, PD and DBS
Description: Sleep, PD and DBS
Study: NCT02613988

Intervention type: DEVICE
Group type: OTHER
Intervention: 3 Tesla magnetic resonance imaging
Description: High resolution structural imaging (contrast-enhanced T1-weighted image, T2-weighted image, Fluid-attenuated inversion recovery)
Study: NCT01094886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: 10mg tablet daily, receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement
Study: NCT03244384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo a MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo a MRI
Study: NCT02613988

Intervention type: DEVICE
Group type: OTHER
Intervention: Chemical exchange saturation transfer MRI
Description: Amide proton transfer-weighted image

Intervention type: DEVICE
Group type: OTHER
Intervention: Diffusion weighted MRI
Description: diffusion-weighted image with b value 0, 1000, and 3000

Intervention type: DEVICE
Group type: OTHER
Intervention: Dynamic susceptibility contrast MRI
Description: dual echo EPI sequence
Study: NCT01627223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Lamivudine 100 mg p.o. q.d.~This process will be stratified by prolonged PT, \< 4 sec / 4-6 sec / \> 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: •Entecavir 0.5 mg p.o. q.d~This process will be stratified by prolonged PT, \< 4 sec / 4-6 sec / \> 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment.
Study: NCT01136213

Intervention type: RADIATION
Intervention: PET (Positron Emission Tomography) Study
Description: 5-HT1a auto-receptors will be visualized in vivo using 18F-MPPF PET study. Two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.

Intervention type: RADIATION
Intervention: PET (Positron Emission Tomography) Study
Description: 5-HT1a auto-receptors will be visualized in vivo using 18F-MPPF PET study. Two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.

Intervention type: RADIATION
Intervention: PET (Positron Emission Tomography) Study
Description: 5-HT1a auto-receptors will be visualized in vivo using 18F-MPPF PET study. Two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.

Intervention type: OTHER
Intervention: Brain MRI (magnetic resonance imaging)
Description: A brain MRI (magnetic resonance imaging)will be performed the day of the first PET study.

Intervention type: OTHER
Intervention: Brain MRI (magnetic resonance imaging)
Description: A brain MRI (magnetic resonance imaging)will be performed the day of the first PET study.

Intervention type: OTHER
Intervention: Brain MRI (magnetic resonance imaging)
Description: A brain MRI (magnetic resonance imaging)will be performed the day of the first PET study.

Intervention type: DRUG
Intervention: Fluoxétine / Placebo
Description: The two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.

Intervention type: DRUG
Intervention: Fluoxétine / Placebo
Description: The two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.

Intervention type: DRUG
Intervention: Fluoxétine / Placebo
Description: The two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.
Study: NCT03460613

Intervention type: OTHER
Group type: OTHER
Intervention: FODMAP diet
Description: Patients with a diagnosed FODMAP intolerance (and a control with no FODMAP intolerance) by prior nutrient challenge testing are going on a FODMAP diet. In a first nutritional visit a specialized nutritionist will inform the patients about FODMAP containing foods and illustrate a FODMAP elimination diet. After 3 weeks of elimination diet another visit will take place and a stepwise reintroduction diet is initiated after successful elimination diet.
Study: NCT04445688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD036
Description: Oral administration before bed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: Oral administration before bed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration before bed